M802 是一种抗 HER2/CD3 双特异性抗体,与人源 HER2 的 Kd 为 0.578 nM,与人源 CD3 的 Kd 为 71.2 nM,可抑制 PI3K/AKT 和 MAPK 信号通路、抑制肿瘤细胞增殖、激活 caspase-3 并促进其凋亡 (apoptosis),同时可募集并激活 CD3 阳性免疫细胞,介导对 HER2 阳性肿瘤细胞的细胞毒性作用,并诱导免疫细胞分泌 IFN-γ、TNF-α、IL-2 和 IL-6,在胃癌异种移植物小鼠中表现出抗肿瘤功效,可用于 HER2 阳性乳腺癌、HER2 阳性胃癌等癌症的相关研究,推荐同型对照为人 IgG1 kappa (MS-E04981)。
M802
产品编号: MS-B93532
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价

产品描述

M802 是一种抗 HER2/CD3 双特异性抗体,与人源 HER2 的 Kd 为 0.578 nM,与人源 CD3 的 Kd 为 71.2 nM,可抑制 PI3K/AKT 和 MAPK 信号通路、抑制肿瘤细胞增殖、激活 caspase-3 并促进其凋亡 (apoptosis),同时可募集并激活 CD3 阳性免疫细胞,介导对 HER2 阳性肿瘤细胞的细胞毒性作用,并诱导免疫细胞分泌 IFN-γ、TNF-α、IL-2 和 IL-6,在胃癌异种移植物小鼠中表现出抗肿瘤功效,可用于 HER2 阳性乳腺癌、HER2 阳性胃癌等癌症的相关研究,推荐同型对照为人 IgG1 kappa (MS-E04981)。

生物实验数据

生物活性 M802 is an anti-HER2/CD3 bispecific antibody with a Kd of 0.578 nM for human HER2 and a Kd of 71.2 nM for human CD3; it inhibits the PI3K/AKT and MAPK signaling pathways, suppresses tumor cell proliferation, activates caspase-3, and promotes apoptosis, while also recruiting and activating CD3-positive immune cells to mediate cytotoxic effects against HER2-positive tumor cells and inducing immune cells to secrete IFN-γ, TNF-α, IL-2, and IL-6, exhibits antitumor efficacy in gastric cancer xenograft mice, and can be used for research related to cancers such as HER2-positive breast cancer and HER2-positive gastric cancer, with the recommended isotype control being human IgG1 kappa (MS-E04981).
IC50 & Target

Human HER2

0.578 nM (Kd)

IL-6

 

Caspase 3

 

IL-2

 

TNF-α

 

体外研究
(In Vitro)

M802 (0-50 nM) 可特异性结合纯化的人源 HER2 和 CD3 胞外域,对 HER2 具有高亲和力 (Kd = 0.578 nM),对 CD3 的亲和力较低 (Kd = 71.2 nM),并且具备同时结合这两种抗原的双重结合能力。
M802 (0.001-1000 nM; 1 h for single cell binding; 0-10 μg/mL; 30 min for co-binding) 可特异性结合 SK-BR-3 细胞上的 HER2 (Kd = 11.71 nM) 以及 Jurkat 细胞上的 CD3 (Kd = 186.8 nM),并介导 HER2 阳性肿瘤细胞与 CD3 阳性 T 细胞之间呈剂量依赖性的细胞聚集体形成。
M802 (0-108 pg/mL; 48 h) 可介导强效的、剂量依赖性的 PBMC 细胞毒性作用,针对 HER2 阳性 SK-BR-3、BT-474、NCI-N87 以及 JIMT-1 肿瘤细胞,而对 HER2 阴性 MDA-MB-231 细胞和非癌细胞 HEK-293 的活性极低。
M802 (0.01-10 μg/mL; 0-6 days) 可剂量依赖性地抑制 HER2 阳性 SK-BR-3 和 BT-474 乳腺癌细胞的增殖、促进细胞凋亡,但对 JIMT-1 细胞增殖无影响。
M802 (0.1-10 μg/mL; 24-48 h) 可在 HER2 阳性 SK-BR-3 和 BT-474 乳腺癌细胞中呈剂量依赖性调控 PI3K/AKT 和 MAPK 信号通路,抑制激酶磷酸化、调控细胞周期蛋白并激活 caspase-3 的凋亡切割。
M802 (0.0001-10000 ng/mL; 48 h) 可在与 HER2 阳性 SK-BR-3 肿瘤细胞及人外周血单个核细胞 (PBMCs) 共培养时,呈剂量依赖性激活 T 细胞并诱导 IFN-γ、TNF-α、IL-2 和 IL-6 的分泌。

Cell Cytotoxicity Assay

Cell Line: human breast cancer SK-BR-3, BT-474, JIMT-1, MDA-MB-231 cells, human gastric cancer NCI-N87 cells, human embryonic kidney HEK-293 cells, peripheral blood mononuclear cells (PBMCs)
Concentration: 0-105 pg/mL (SK-BR-3, NCI-N87, BT-474, JIMT-1); 10-2-108 pg/mL (MDA-MB-231); 100-105 pg/mL (HEK-293)
Incubation Time: 48 h
Result: Induced potent, dose-dependent cytotoxicity against HER2-positive SK-BR-3 (EC50 = 782.7 pg/mL, maximum lysis = 74.71%).
Induced potent, dose-dependent cytotoxicity against HER2-positive BT-474 (EC50 = 2808 pg/mL, maximum lysis = 93.90%).
Induced potent, dose-dependent cytotoxicity against HER2-positive NCI-N87 (EC50 = 833.9 pg/mL, maximum lysis = 78.40%).
Induced potent, dose-dependent cytotoxicity against Herceptin-resistant JIMT-1 (EC50 = 39365 pg/mL, maximum lysis = 94.89%).
Showed minimal cytotoxicity against HER2-negative MDA-MB-231 (maximum lysis = 50.58%).
Showed minimal cytotoxicity against non-cancerous HEK-293 (maximum lysis = 12.78%).

Cell Proliferation Assay

Cell Line: human breast cancer SK-BR-3, BT-474, and JIMT-1 cells
Concentration: 0.01, 0.1, 1, 10 μg/mL
Incubation Time: 0-6 days
Result: Exhibited dose-dependent inhibition of proliferation in SK-BR-3 and BT-474 cells, with effects becoming apparent after day 4, though this inhibition was weaker than that of Herceptin.
Had no inhibitory effect on Herceptin-resistant JIMT-1 cell proliferation.

Apoptosis Analysis

Cell Line: human breast cancer SK-BR-3, BT-474, and JIMT-1 cells
Concentration: 0.1, 1, 10 μg/mL
Incubation Time: 48 h
Result: Significantly increased the apoptotic ratio of SK-BR-3 and BT-474 cells in a dose-dependent manner, with the highest effect at 10 μg/mL.
Showed no statistically significant difference in apoptosis induction in JIMT-1 cells compared to Herceptin, and neither induced meaningful apoptosis in this resistant cell line.

Western Blot Analysis

Cell Line: human breast cancer SK-BR-3, BT-474, and JIMT-1 cells
Concentration: 0.1, 1, 10 μg/mL
Incubation Time: 24 h (Akt/p-Akt, Erk/p-Erk); 48 h (cyclin D1, p21, p27, caspase-3, cleaved-caspase-3)
Result: Caused dose-dependent inhibition of Akt and Erk phosphorylation, downregulation of cyclin D1, upregulation of p21 and p27, and increased levels of cleaved-caspase-3 in SK-BR-3 and BT-474 cells.
Had no effect on p-Akt or p-Erk levels in JIMT-1 cells.
体内研究
(In Vivo)

M802 (1-2 mg/kg;静脉注射;于第 0、2、4 天推注给药) 在携带有 NCI-N87 胃癌异种移植物的 NOD/SCID 小鼠中表现出显著的剂量依赖性抗肿瘤功效。

Animal Model: NOD/SCID (female, 7 to 8 weeks old)
Dosage: 1 mg/kg; 2 mg/kg
Administration: i.v.; bolus injection on day 0, day 2, day 4
Result: Achieved complete inhibition of tumor growth throughout the 53-day observation period (2 mg/kg).
Showed significant tumor growth inhibition, with small nodules observed only during the later period of the study, and an inhibitory effect similar to that of 4 mg/kg Herceptin (1 mg/kg).

化学信息

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础